GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
Surely every day that passes now you would expect a small increase as we near the results and knowing that they would have been kicked out of the trials if they weren’t working. To me it’s common sense that the odds slowly change in our favour daily.
I bought in at 25p. Thought it was a bargain. Hindsight is often painful but I am optimistic and I was happy to pay 25p.
We are extremely vulnerable at a take over at too cheap a price, I am very concerned, we could lose out here. I am confident RM will fight back, I also wouldn't be surprised to see a few potential bidders.
Florida perhaps brew a chaser and call it “sucksess “
Ok I understand what’s happened with the “in vitro” and I would have assumed this was done in Southampton ages ago. So really this is just more affirmation that this works? Building blocks I guess to a castle.
This is the $64000000 question, everyone here holding shares is thinking the same thing, they are thinking that surely this is nailed on! Surely someone would have found a flaw somewhere by now! Am I being an idiot or is there a massive problem that i can't see!
The main point is in all of this is that its a single play on a single drug and **** happens! I am so heavy into this for all the reasons above, I am looking forward to meeting all the high profile posters (FloridaJoe Particularly) at the Pompey bash and hearing all the stories of 'whats and ifs'.
The only thing we need before the positive results is patience and patients.
This was from the company less than 6 months ago. Things have only improved not worsened.
Positive results from SG016, its double-blind placebo-controlled Phase II trial of SNG001 in hospitalised COVID-19 patients announced in July
The Company extended the SG016 Phase II trial to include a further 120 patients with confirmed COVID-19 to be dosed in the home environment (ongoing)
Positive results from interim analysis of SG015, its double-blind placebo-controlled Phase II trial of SNG001 in COPD patients announced in September, supporting the COVID-19 programme
Patent applications for SNG001 in COVID-19 patients and in exacerbating COPD patients undergoing treatment with systemic corticosteroids were submitted post period-end
Synairgen launched a Managed Access Program with Clinigen, to provide SNG001 to hospitalised COVID-19 patients – see separate announcement issued today
The Company is currently in discussions with regulatory agencies to establish the route to approval of SNG001 as a treatment for COVID-19
The Company is also investing in supply chain activities to ensure that drug and aerosol delivery system availability can meet potential demand, pending approval